�ʼһ���

Our website aims to support child health professionals’ understanding and practice of embedding QI in their work environments. It features resources and examples of interventions in patient-centred care, medicines and systems of care.

We have worked with NHS England on a programme to ensure children and young people with a learning disability, autism or both are able to access appropriate medication, and are not prescribed inappropriate psychotropic medication. Find out more and read our full pledge.

The Neonatal and Paediatric Pharmacy Group (NPPG) and the Royal College of Paediatrics and Child Health (RCPCH) strongly recommend that when children require liquid medications, they should receive the RCPCH and NPPG recommended concentrations, where one exists. There are currently 13 such recommend...

The aim of this evidence-based statement is to summarise the current knowledge about delayed prescriptions (also called backup prescriptions) for antibiotics and to highlight the special issues that must be taken into account when considering the need for a delayed prescription in infants and childr...

RCPCH responds to new research which suggests these drugs may alter gut microbes associated with weight gain.

The following case study from Calderdale and Huddersfield NHS Foundation Trust was included in the 2018 annual report on 2017 data, and highlights how NNAP results can be used as a basis for identifying, and undertaking, local quality improvement activities.

This case study from Watford General Hospital, West Hertfordshire NHS Trust was included in the 2018 annual report on 2017 data, and highlights how some neonatal units have used NNAP results as a basis for identifying, and undertaking, local quality improvement activities.

Our medicines information resource for parents and children is shortlisted for the “Optimisation of Medicines Management” category of the Health Service Journal Award, which celebrates healthcare excellence.

The Royal College of Paediatrics and Child Health and British Paediatric Neurology Association has developed this Q&A in light of recent developments in this area. It advises on the legality and safety of cannabis-based products and considers the evidence base for their potential harms and benefits.

RCPCH Registrar, Dr Mike Linney, says the decision will 'come as a relief for some'. He warns parents in the meantime to not give children unlicensed cannabinoid oil products.